|
 |
 |
 |
 |
 |
 |
 |
 |
 |
Select Publications
Jones SE et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 2006;24(34):5381-7. Abstract
Lenihan DJ et al. Withdrawal of ACE inhibitors and beta-blockers in cancer patients with congestive heart failure leads to severe cardiovascular adverse events. J Card Fail 2003;9(Suppl 5):77;Abstract 281. No abstract available
Pegram M et al. Phase II combined biological therapy targeting the HER2 proto-oncogene and the vascular endothelial growth factor using trastuzumab (T) and bevacizumab (B) as first line treatment of HER2-amplified breast cancer. San Antonio Breast Cancer Symposium 2006; Abstract 301.
Pinder MC et al. Congestive heart failure in older women treated with adjuvant anthracyclines chemotherapy for breast cancer. J Clin Oncol 2007;25(25):3808-15. Abstract
Rastogi P et al. Five year update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC) 
paclitaxel (T) vs AC T with trastuzumab (H). Proc ASCO 2007;Abstract LBA513.
Slamon D et al. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients. San Antonio Breast Cancer Symposium 2006; Abstract 52.
Smith I et al; HERA study team. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. Lancet 2007;369(9555):29-36. Abstract
 |
 |
